Severe epileptic disorders such as Lennox-Gastaut syndrome (LGS) are commonly associated with various types of seizures and cognitive dysfunction that persist into adulthood.^[@ref1]^ As a result, these patients suffer from varying degrees of learning disabilities, psychiatric disorders, and behavioral abnormalities that can drastically affect their social integration.^[@ref1]^ Diagnosis and subsequent management of LGS are challenging, relying mostly on the expertise of the physician to interpret an intricate amalgamation of clinical and EEG abnormalities.^[@ref2]^ Although limited clinical trials suggest that a small subset of available anti-epileptic drugs (AEDs) such as lamotrigine, valproic acid, topiramate, felbamate, and clobazam may be used to manage the multiple seizure types associated with LGS, their efficacy is often inadequate, and perilous adverse effects may occur.^[@ref2]^ The relatively new drug rufinamide, a compound with orphan drug status in the United States and marketing authorization in Europe, displays a broad spectrum of anti-epileptic activity, and clinical trials have shown long-term beneficial effects and good tolerability when rufinamide is used as adjunctive therapy in children and adults suffering from LGS.^[@ref3],[@ref4]^ As such, rufinamide is poised to replace the more adverse effect-prone classical AEDs as a valuable treatment for LGS^[@ref5]^ as well as partial^[@ref3]^ or refractory focal^[@ref6]^ seizures. Interestingly, the hydrophobic triazole-derived molecular structure of rufinamide is unlike that of any other anti-epileptic compound;^[@ref4]^ nonetheless, the drug is absorbed extensively when taken orally, and dosages of up to 3200 mg/day are common.^[@ref4],[@ref7],[@ref8]^

Given their unique role in electrical signaling^[@ref9]^ and subsequent implications in various epilepsy disorders,^[@ref10]−[@ref14]^ voltage-gated sodium (Na~v~) channels within the central nervous system (CNS) may be influenced by rufinamide;^[@ref15],[@ref16]^ however, it is unclear whether modulating a particular isoform constitutes the primary mode of action. Of the nine Na~v~ channel isoforms (Na~v~1.1--Na~v~1.9) identified in humans, four are expressed predominantly in the CNS \[Na~v~1.1 (*SCN1A*), Na~v~1.2 (*SCN2A*), Na~v~1.3 (*SCN3A*), and Na~v~1.6 (*SCN8A*)\].^[@ref9],[@ref17]^ Supporting their physiological importance, mutations in Na~v~1.1,^[@ref12],[@ref18],[@ref19]^ Na~v~1.2,^[@ref13]^ and Na~v~1.6^[@ref20],[@ref21]^ have been linked to various epilepsy phenotypes, whereas Na~v~1.3 is believed to be involved also in nociception after channel upregulation due to spinal cord injury.^[@ref22]−[@ref24]^ Consequently, we set out to investigate whether rufinamide influences the functional properties of one or more of these four Na~v~ channel isoforms. To this end, we transiently expressed human (h) hNa~v~1.1, hNa~v~1.2, hNa~v~1.3, and hNa~v~1.6 in a robust heterologous expression system and found that a clinically relevant rufinamide concentration primarily influences the voltage dependence of hNa~v~1.1 activation and availability of hNa~v~1.6 channels, whereas the recovery from fast inactivation of hNa~v~1.1, hNa~v~1.2, hNa~v~1.3, and hNa~v~1.6 is only slightly altered. Subsequent experiments with structurally related compounds reveal that chemical derivatization at particular positions on the triazole pharmacophore may be exploited to obtain specific inhibition of hNa~v~1.1 activation, thereby increasing seizure thresholds in rodent models of epilepsy.

Results {#sec3}
=======

Expressing Human Na~v~ Channel Isoforms in *Xenopus* Oocytes {#sec3.1}
------------------------------------------------------------

To identify the molecular target of rufinamide in the brain, we examined potential drug-induced alterations of human neuronal Na~v~ channel opening and closing (i.e., gating). Although stable cell lines of hNa~v~1.1, hNa~v~1.2, hNa~v~1.3, and hNa~v~1.6 have been reported,^[@ref29]−[@ref32]^ DNA rearrangement events and low protein levels have hampered in-depth experiments with these genes in *Xenopus laevis* oocytes, a transient and robust heterologous expression system widely used to address fundamental questions about the gating mechanisms and pharmacological sensitivities of individual ion channel isoforms. By combining careful full-length clone sequencing with transformations of cDNA modified with an ER forwarding motif^[@ref25]^ and the rNa~v~1.2a 3′UTR region into low-copy *Escherichia coli* variants (CopyCutter EPI400), we were able to consistently obtain robust ionic currents for all four human Na~v~ channel isoforms in *Xenopus* oocytes (Figure S1 of the [Supporting Information](#notes-2){ref-type="notes"}). Examination of the G--V relationships for hNa~v~1.1, hNa~v~1.2, hNa~v~1.3, and hNa~v~1.6 (Figure S1 of the [Supporting Information](#notes-2){ref-type="notes"}) reveals that the midpoints (*V*~1/2~) for channel activation are −37.8, −31.4, −25.4, and −36.7 mV, respectively (Table [1](#tbl1){ref-type="other"}). Although the same relative order of midpoints is essentially observed in mammalian cell recordings,^[@ref29]−[@ref32]^ their absolute values as well as those from channel availability and recovery from inactivation measurements (Figure S1 of the [Supporting Information](#notes-2){ref-type="notes"} and Table [1](#tbl1){ref-type="other"}) differ noticeably, yet this observation is not surprising considering the variability in lipid membrane, glycosylation, and auxiliary subunit composition between diverse cell types. Next, we applied rufinamide to hNa~v~1.1--hNa~v~1.3 and hNa~v~1.6 to determine whether the drug alters channel gating.

###### Effects of 100 μM Rufinamide and Its Derivatives on Human Na~v~ Channel Isoforms[a](#tbl1-fn1){ref-type="table-fn"}

                                              hNa~v~1.1        hNa~v~1.2      hNa~v~1.3      hNa~v~1.6
  ------------ ------------------------------ ---------------- -------------- -------------- ----------------
  control      activation (*V*~1/2~) (mV)     --37.8 ± 1.7     --31.4 ± 1.5   --25.4 ± 1.4   --29.0 ± 2.2
               inactivation (*V*~1/2~) (mV)   --52.9 ± 1.0     --57.1 ± 0.3   --52.2 ± 0.7   --64.8 ± 1.2
               recovery (T) (ms)              3.4 ± 0.2        6.6 ± 0.5      5.6 ± 0.3      4.4 ± 0.3
  DMSO         activation (*V*~1/2~) (mV)     --38.2 ± 1.9     --31.7 ± 1.2   --24.7 ± 1.6   --26.7 ± 1.1
               inactivation (*V*~1/2~) (mV)   --49.4 ± 0.3     --59.7 ± 0.4   --52.8 ± 0.9   --65.1 ± 0.8
               recovery (T) (ms)              3.8 ± 0.5        7.1 ± 0.4      6.5 ± 0.3      5.0 ± 0.4
  rufinamide   activation (*V*~1/2~) (mV)     --30.6 ± 0.9\*   --29.5 ± 1.2   --24.5 ± 2.4   --28.1 ± 0.8
               inactivation (*V*~1/2~) (mV)   --47.8 ± 1.6     --57.7 ± 0.5   --52.6 ± 1.6   --60.0 ± 0.7\*
               recovery (T) (ms)              5.1 ± 0.2\*      10.6 ± 0.3\*   9.2 ± 0.5\*    7.4 ± 0.3\*

                                             compound A       compound B       compound C     compound D
  ----------- ------------------------------ ---------------- ---------------- -------------- --------------
  hNa~v~1.1   activation (*V*~1/2~) (mV)     --30.8 ± 1.0\*   --27.4 ± 1.0\*   --38.4 ± 1.3   --32.5 ± 2.3
              inactivation (*V*~1/2~) (mV)   --50.5 ± 1.2     --49.4 ± 0.3     --49.2 ± 0.6   --49.8 ± 1.6
              recovery (*T*) (ms)            4.1 ± 0.5        3.9 ± 0.1        3.1 ± 0.1      3.9 ± 0.3

Drug values are compared to DMSO values for statistical comparison, which is considered significant if the result of the Student's *t* test indicated a *p* of \<0.005 (denoted with asterisks).

The Gating Process of Human Na~v~ Channels Is Altered by Rufinamide {#sec3.2}
-------------------------------------------------------------------

Rufinamide, or 1-\[(2,6-difluorophenyl)methyl\]-1*H*-1,2,3-triazole-4-carboxamide,^[@ref4]^ is slightly soluble in water but dissolves readily in dimethyl sulfoxide (DMSO) at concentrations of up to 9 mg mL^--1^ (Figure [1](#fig1){ref-type="fig"}A). As such, patients are given the drug either as a tablet formulation (Banzel) or as an oral suspension (Inovelon), preferably to be taken with food.^[@ref7]^ On the basis of these properties, we dissolved rufinamide in DMSO and diluted this stock solution with appropriate recording media to a final concentration of 100 μM, thereby approximating clinically observed serum quantities.^[@ref4],[@ref8],[@ref33]^ Subsequently, Na~v~ channel-expressing cells were exposed to 100 μM rufinamide in a solution containing at most 1% DMSO. Control experiments without the drug revealed that the gating properties of hNa~v~1.1, hNa~v~1.2, hNa~v~1.3, and hNa~v~1.6 are not significantly affected upon exposure to 1% DMSO (Figure S2 of the [Supporting Information](#notes-2){ref-type="notes"} and Table [1](#tbl1){ref-type="other"}). Hereafter, we will consider the gating parameters from DMSO-treated Na~v~ channel isoforms to be our control values.

![Effect of 100 μM rufinamide on human Na~v~ channel isoforms involved in epilepsy. (A) Molecular organization of rufinamide consisting of the 1,2,3-triazole ring connecting the 2,6-difluorophenyl and the carboxamide. (B--E) The left column shows *G*/*G*~max~ and *I*/*I*~max~ relationships, whereas the right column displays the recovery from fast inactivation. The figure shows that rufinamide inhibits hNa~v~1.1 opening whereas the effect on hNa~v~1.6 is not significant compared to the effect of DMSO treatment of this particular isoform (see Table [1](#tbl1){ref-type="other"}). Furthermore, the recovery from fast inactivation slows for the four Na~v~ channel isoforms tested here. All data are shown before (green, DMSO control) and after (red) addition of 100 μM rufinamide to hNa~v~1.1 (B), hNa~v~1.2 (C), hNa~v~1.3 (D), and hNa~v~1.6 (E). All fit values are listed in Table [1](#tbl1){ref-type="other"}. *n* = 5--8, and error bars represent the standard error of the mean.](cb-2014-00108p_0001){#fig1}

After incubating oocytes with 100 μM rufinamide, we observed an ∼8 mV depolarizing shift in the *G*--*V* relationship of hNa~v~1.1, whereas the activation of hNa~v~1.2, hNa~v~1.3, and hNa~v~1.6 is not inhibited (Figure [1](#fig1){ref-type="fig"} and Table [1](#tbl1){ref-type="other"}). In contrast, steady-state inactivation of hNa~v~1.1, hNa~v~1.2, and hNa~v~1.3 is not influenced; however, 100 μM rufinamide does alter the midpoint of hNa~v~1.6 channel availability by approximately +5 mV (Figure [1](#fig1){ref-type="fig"} and Table [1](#tbl1){ref-type="other"}). Moreover, recovery from fast inactivation slows for all tested Na~v~ channel isoforms (Figure [1](#fig1){ref-type="fig"} and Table [1](#tbl1){ref-type="other"}), and although these effects are subtle, the combination with a substantial shift in hNa~v~1.1 activation voltage may help explain a decrease in neuronal excitability after administration of the drug.^[@ref15]^ Altogether, our experiments with four neuronal Na~v~ channel isoforms suggest that rufinamide primarily influences hNa~v~1.1 and hNa~v~1.6 function, an observation that supports a role of these particular Na~v~ channel variants in epilepsy syndromes.^[@ref10],[@ref12]−[@ref14],[@ref18],[@ref20],[@ref21]^ It is worth noting that rufinamide may alter hNa~v~1.1 activation by influencing voltage-sensor activation or by slowing subsequent gating transitions,^[@ref34]^ a distinct working mechanism among the classic anticonvulsant drugs because these compounds are thought to exert their effect by (1) occluding the pore to prevent sodium ion flow or (2) interacting with the inactivated state to decrease the size of the pool of channels available for opening.^[@ref33],[@ref35]−[@ref37]^ Next, we wanted to explore whether particular structural features of the rufinamide molecule can enhance hNa~v~1.1 selectivity.

Molecular Modifications of Rufinamide Enhance the Effects on hNa~v~1.1 {#sec3.3}
----------------------------------------------------------------------

The triazole-derived molecular organization of rufinamide is unique among anti-epileptic compounds.^[@ref4]^ To examine which features of the *N*-benzyltriazole core are important for its inhibitory action on hNa~v~1.1, we performed a structure--activity relationship (SAR) study using four structurally related compounds with unknown functionality: 1-\[(3-fluorophenyl)methyl\]-1*H*-1,2,3-triazole-4-carboxamide-5-amine (compound A), 1-(phenylmethyl)-1*H*-1,2,3-triazole-4-carboxamide-5-methyl (compound B), 1-\[(3-fluorophenyl)methyl\]-1*H*-1,2,3-triazole-4-hydroxymethyl (compound C), and 1-\[(4-fluorophenyl)methyl\]-1*H*-1,2,3-triazole-4-carboxamide-5-amine (compound D). We found that compounds A and B inhibit hNa~v~1.1 opening (Figure [2](#fig2){ref-type="fig"} and Table [1](#tbl1){ref-type="other"}) and compound B produces the largest depolarizing shift in channel activation voltage (approximately +11 mV). Strikingly, neither of these compounds influences hNa~v~1.1 steady-state inactivation, recovery from inactivation, or the persistent current^[@ref38]^ (Figures S3 and S4A,B of the [Supporting Information](#notes-2){ref-type="notes"} and Table [1](#tbl1){ref-type="other"}), suggesting a working mechanism geared toward stabilizing a closed state of this particular Na~v~ channel isoform. In contrast to the effect of rufinamide, application of 100 μM compound B selectively modulates hNa~v~1.1 activation whereas the tested gating parameters of hNa~v~1.2, hNa~v~1.3, and hNa~v~1.6 are unaltered (Figure S5 and Table S1 of the [Supporting Information](#notes-2){ref-type="notes"} and Table [1](#tbl1){ref-type="other"}). Moreover, our results suggest that rufinamide and compound B do not influence the entry into or voltage dependence of hNa~v~1.1 slow inactivation (Figure S6 and Table S2 of the [Supporting Information](#notes-2){ref-type="notes"}).^[@ref39]^ Finally, rufinamide and compound B (100 μM) do not activate the α1/β2/γ2 GABA~A~ receptor (Figure S4C of the [Supporting Information](#notes-2){ref-type="notes"}), a subtype ubiquitously found in GABAergic neurons that is targeted by psychoactive drugs such as zolpidem and benzodiazepines.^[@ref40]^ Also, neither drug inhibits hERG,^[@ref27]^ a member of the cardiac potassium channel family and an FDA-mandated screening target for potential off-target drug effects (Figure S7 of the [Supporting Information](#notes-2){ref-type="notes"}).

![Effect of rufinamide derivatives on hNa~v~1.1. (A--D) The left column shows *G*/*G*~max~ relationships before (green, DMSO control) and after (red) addition of 100 μM rufinamide derivatives fitted with the Boltzmann equation. Compounds A and B clearly inhibit hNa~v~1.1 opening, whereas compound C no longer affects hNa~v~1.1 opening (compound D is not significant when considering *p* \< 0.005). Fit values are listed in Table [1](#tbl1){ref-type="other"}. *n* = 5--8, and error bars represent the standard error of the mean. The right column displays the molecular organization of the four tested derivatives (compounds A--D).](cb-2014-00108p_0002){#fig2}

One of the most captivating results from our SAR studies is that compound B inhibits hNa~v~1.1 more efficaciously than rufinamide (Figure [2](#fig2){ref-type="fig"} and Table [1](#tbl1){ref-type="other"}). The identification of such a molecule is particularly exciting as it underlines the broad scope of rufinamide scaffold-based drug development for treating hNa~v~1.1-related disorders. Upon comparison of the structures of rufinamide and compound B, two differences stand out. On one hand, rufinamide has two electron-withdrawing fluoro substituents on the phenyl group whereas compound B has none, thereby rendering the phenyl group of this molecule more electron-rich. On the other hand, there is an additional methyl substituent on the triazole ring in compound B, resulting in an increased level of hydrophobic character increased compared to that of rufinamide. Another important observation from our experiments is that compound D has diminished activity whereas compound C no longer influences hNa~v~1.1 gating at all (Figure [2](#fig2){ref-type="fig"}c). The most significant structural feature of compound C is the presence of a methylene hydroxyl (-CH~2~OH) group on its triazole moiety; an amide (-CONH~2~) substituent is found in the other compounds. To determine whether compound B is physiologically active, we next examined the activity of this molecule in hippocampal neurons.

Compound B Increases the Action Potential Threshold in Hippocampal Neurons {#sec3.4}
--------------------------------------------------------------------------

The Na~v~1.1 distribution is strikingly similar in human and rodent brains.^[@ref41]^ Moreover, 99% of the amino acids that make up Na~v~1.1 are conserved among humans, rats, and mice (ClustalΩ^[@ref42]^). As such, we expect the inhibitory effect of compound B to increase the action potential threshold in Na~v~1.1-expressing rat hippocampal neurons. To test this hypothesis, we applied a physiological solution containing 100 μM compound B to cultured hippocampal neurons and found that a current injection of 80 pA elicits an action potential (Figure [3](#fig3){ref-type="fig"}a). In contrast, hippocampal neurons under control conditions require a current injection of only 20 pA to start generating action potentials (Figure [3](#fig3){ref-type="fig"}A). When assessing average firing thresholds by calculating the potential at which the rate of rise crosses 40 V/s, we observe a value of −43.3 ± 2.4 mV for control cells, whereas a threshold of −27.8 ± 1.6 mV is noted when cells are treated with 100 μM compound B (Figure [3](#fig3){ref-type="fig"}B). Altogether, these results suggest an ability of compound B to reduce the level of action potential firing in hippocampal neurons by shifting the firing threshold in the depolarizing direction, possibly by deferring Na~v~1.1 channel activation to more positive membrane voltages (Figure [2](#fig2){ref-type="fig"}B, Figure S5 of the [Supporting Information](#notes-2){ref-type="notes"}, and Table [1](#tbl1){ref-type="other"}). Subsequently, we examined the biological activity of this molecule in three established mouse epilepsy models.

![Effect of compound B on rat hippocampal neurons. (A) Representative recordings of cells treated with DMSO-containing vehicle (left) vs cells treated with 100 μM compound B (right). The inset shows the current clamp protocol of a series of 10 pA depolarizing current injections in which red and green indicate the current needed to elicit an action potential under control conditions (20 pA) and that of the treated cells (80 pA), respectively. (B) Average action potential thresholds are significantly higher in cells treated with compound B \[−27.8 ± 1.6 mV (○); *n* = 7\] than in cells treated with the DMSO-containing vehicle \[−43.3 ± 2.4 mV (●); *n* = 7\].](cb-2014-00108p_0003){#fig3}

Compound B Is Effective in Rodent Seizure Induction Paradigms {#sec3.5}
-------------------------------------------------------------

First, we tested compound B in the picrotoxin seizure induction assay, a widely used epilepsy model based on inhibiting GABA-mediated synaptic transmission. On the basis of the effective dose of rufinamide reported previously,^[@ref5]^ we tested compound B at a dose of 75 mg/kg. Even though the forelimb clonus (FC) tends to occur later in the compound B-treated mice, we observe no statistically significant differences between vehicle- and compound B-treated mice in their average latencies to the first myoclonic jerk (MJ) (*p* = 0.4) and FC (*p* = 0.3) (Figure [4](#fig4){ref-type="fig"}). However, the average latency to the first generalized tonic-clonic seizure (GTCS) following treatment with compound B is significantly increased by 41% (1693 ± 315 s; *p* = 0.03) compared to that of vehicle-treated mice (1006 ± 106 s). There is no difference in the frequency of the behavioral seizures between the treatment groups.

![Compound B increases latencies to picrotoxin- and fluorothyl-induced generalized seizures. (A) Picrotoxin (10 mg/kg) was administered to vehicle-treated (black) and compound B-treated (red) male Crl:CF1 mice (75 mg/kg) 15 min prior to seizure induction. The average latencies in seconds to the first myoclonic jerk (MJ), forelimb clonus (FC), and generalized tonic-clonic seizure (GTCS) are compared. Compound B increases the average latency to the first GTCS. \**p* \< 0.05. Error bars represent the standard error of the mean. (B) The latencies to the MJ, GTCS, and GTCS with hind limb extension (GTCS+) in the fluorothyl model are compared between vehicle-treated (black) and compound B-treated (red) male Crl:CF1 mice (75 mg/kg). The average latencies in seconds to the GTCS and GTCS+ are significantly longer in the compound B-treated mice. \*\*\**p* \< 0.001. Error bars represent the standard error of the mean.](cb-2014-00108p_0004){#fig4}

Because one assay may not accurately reflect the ability of a drug to increase seizure resistance, we next investigated compound B efficacy in the fluorothyl paradigm, an established seizure induction model involving exposure of the animal to the volatile proconvulsant bis-2,2,2-trifluoroethyl ether.^[@ref43]^ Although the average latency to the MJ is comparable between vehicle- and compound B-treated mice (*p* = 0.6), the average latencies to the first GTCS and GTCS with hind limb extension (GTCS+) are increased by 43 and 56%, respectively (*p* \< 0.0001; 652 ± 48 s for GTCS and 1155 ± 89 s for GTCS+), compared to those of the vehicle-treated group (281 ± 19 and 652 ± 38 s, respectively) (Figure [5](#fig5){ref-type="fig"}). These results clearly demonstrate that compound B successfully increases the average latency to fluorothyl-induced GTCS and GTCS+.

![Compound B reduces the severity of seizures induced by the 6 Hz psychomotor paradigm. A current intensity of 17 mA was used to induce partial seizures in vehicle-treated (black) and compound B-treated (red) male Crl:CF1 mice (75 mg/kg). Following treatment with compound B, there is a 63% reduction in the number of mice exhibiting seizures (A; *p* \< 0.0001). In addition, the seizures that were observed in the compound B-treated mice are typically less severe than those seen in the vehicle-treated mice (black) (B; *p* \< 0.0001). Error bars represent the standard error of the mean.](cb-2014-00108p_0005){#fig5}

Finally, we examined whether compound B is capable of reducing the occurrence and severity of seizures observed in the 6 Hz seizure induction paradigm, a model with a proven track record in drug development.^[@ref44]^ At a current intensity of 17 mA, 92% (*n* = 22 out of 24) of vehicle-treated mice display behavioral seizures and the majority of the observed seizures can be characterized as forelimb clonus (Racine score of 2) or rearing and falling (Racine score of 3) (Figure [5](#fig5){ref-type="fig"}). In sharp contrast, only 29% (*n* = 7 out of 24; *p* \< 0.0001) of the compound B-treated animals exhibit behavioral seizures, which are also dramatically less severe compared to those seen in the vehicle-treated mice (*p* \< 0.0001). Overall, these results substantiate the notion that it is possible to achieve seizure resistance by modifying the *N*-benzyltriazole scaffold of rufinamide to target hNa~v~1.1 activation.

Discussion {#sec4}
==========

The results presented here together with previously reported observations^[@ref15],[@ref16],[@ref33]^ suggest that the anti-epileptic drug rufinamide primarily targets the hNa~v~1.1 and hNa~v~1.6 isoforms in the brain (Figure [1](#fig1){ref-type="fig"} and Table [1](#tbl1){ref-type="other"}). However, it is worth mentioning that additional mechanisms of action cannot be ruled out. For example, in an effort to find drugs for neuropathic pain, researchers found that rufinamide stabilizes the inactivated state of the Na~v~1.7 isoform that is typically found in the peripheral nervous system.^[@ref33],[@ref45]^ Although this effect is rather small compared to that on hNa~v~1.1 activation voltage, it may contribute to a beneficial effect of rufinamide in patients with febrile seizures.^[@ref46]^ Because anomalous hNa~v~1.1 behavior has been implicated in LGS,^[@ref1],[@ref2],[@ref47]−[@ref49]^ the therapeutic effects of rufinamide may indeed stem from its ability to shift the voltage dependence of activation of hNa~v~1.1 channels to more positive potentials (Figure [1](#fig1){ref-type="fig"} and Table [1](#tbl1){ref-type="other"}), a notion worth exploring for treating disorders involving hNa~v~1.1 gain-of-function mutations such as GEFS+,^[@ref10],[@ref14],[@ref18],[@ref50]−[@ref53]^ migraine,^[@ref54],[@ref55]^ and post-traumatic stress disorder.^[@ref56]^ However, rufinamide may be contraindicated with patients in whom Na~v~1.1 function is already impaired. For instance, Na~v~1.1 deletion in mouse hippocampal and cortical interneurons decreases the level of sustained high-frequency firing of action potentials by reducing the overall sodium current without altering its voltage-dependent features.^[@ref28],[@ref57],[@ref58]^ Subsequently, loss of Na~v~1.1 function may lead to hyperexcitability and epileptic seizures in patients with Dravet syndrome^[@ref58]^ and autism.^[@ref59],[@ref60]^ Although more experiments are needed to explain this phenomenon, it is worth noting that Na~v~1.1 deletion in mice causes Na~v~1.3 to be upregulated,^[@ref58]^ one of several observations that highlight a delicate balance between various signaling components involved in cellular excitation and inhibition that, in turn, complicates the translation of inhibitory anticonvulsant efficacy from heterologous expression systems to an intricate neuronal circuit.^[@ref11],[@ref15],[@ref35],[@ref36],[@ref61]^

Intrigued by the unique molecular organization of rufinamide (Figure [1](#fig1){ref-type="fig"}A), we examined which features of the *N*-benzyltriazole core contribute most to its inhibitory effect on hNa~v~1.1. As a result, three important features that need to be considered for hNa~v~1.1 drug development using the *N*-benzyltriazole scaffold emerge from our SAR study. First, tweaking the electron density of the phenyl ring by removing or repositioning electron-withdrawing fluoro groups is a strategy worth exploring. Second, increasing triazole ring hydrophobicity by introducing alkyl substituents may give rise to molecules with better hNa~v~1.1 efficacy. Third, an amide substituent on the triazole ring plays an important role in imparting hNa~v~1.1 selectivity to rufinamide and its analogues. Considering these results, it will be very insightful to synthesize a series of rufinamide analogues bearing different alkyl chains in combination with varying electron density-altering substituents on the phenyl group and then test their efficacy as anti-epileptic agents. Subsequently, we identified a molecule with the properties mentioned above that does not influence hNa~v~1.2, hNa~v~1.3, or hNa~v~1.6 activation or steady-state inactivation (compound B in Figure [2](#fig2){ref-type="fig"}B) and examined its effect on Na~v~1.1-expressing cultured hippocampal neurons (Figure [3](#fig3){ref-type="fig"}). As anticipated when shifting the Na~v~ channel activation voltage, we observed a significant increase in the action potential threshold (∼16 mV) in the presence of 100 μM compound B (Figure [3](#fig3){ref-type="fig"}), an exciting result that motivated us to translate our findings to three rodent models of epilepsy. Consistent with a role for Na~v~1.1 in prompting neuronal firing, we found that compound B is capable of increasing the average latency to the GTCS in the picrotoxin (Figure [4](#fig4){ref-type="fig"}) and fluorothyl paradigms (Figure [5](#fig5){ref-type="fig"}). In addition, compound B reduces seizure occurrence and severity in the 6 Hz seizure induction assay (Figure [5](#fig5){ref-type="fig"}), a model previously employed to successfully identify anticonvulsant drugs such as tiagabine,^[@ref62]^ vigabatrin,^[@ref62]^ and lacosamide.^[@ref63]^ Overall, these results demonstrate that modifying the unique *N-*benzyltriazole scaffold of rufinamide can produce biologically active molecules that target hNa~v~1.1 opening, an outcome that may be exploited in the design of suitable compounds for investigating the functional role of hNa~v~1.1 in healthy and diseased tissues or for treating hNa~v~1.1-related gain-of-function disorders such as GEFS+^[@ref10],[@ref14],[@ref18],[@ref50]−[@ref53]^ and migraine.^[@ref54],[@ref55]^ Consistent with the protection achieved in wild-type mice, compound B in particular may also find use as a general anticonvulsant. A more comprehensive interpretation of our results is that they provide a conceptual example for designing drugs that interact with specific Na~v~ channel isoforms, a necessary feature for reducing unwanted adverse effects.

Methods {#sec2}
=======

Channel Constructs {#sec2.1}
------------------

Human (h) hNa~v~1.1 (NM_001165963.1), hNa~v~1.2 (NM_021007.2), hNa~v~1.3 (NM_006922.3), hNa~v~1.6 (NM_014191.3), and hβ~1~ (NM_001037.4) clones were obtained from OriGene Technologies, Inc., and modified with an ER forwarding motif^[@ref25]^ and the rNa~v~1.2a 3′UTR region for expression in *Xenopus laevis* oocytes (acquired from *Xenopus* One). To check for undesired rearrangement events, the DNA sequence of all constructs was confirmed by automated DNA sequencing before further usage. cRNA was synthesized using T7 polymerase (Life Technologies) after the DNA had been linearized with the appropriate restriction enzymes.

Two-Electrode Voltage-Clamp Recording from *Xenopus* Oocytes {#sec2.2}
------------------------------------------------------------

Channels were expressed in *Xenopus* oocytes together with β~1~ in a 1:5 molar ratio, and currents were studied following incubation for 1--2 days after cRNA injection \[incubated at 17 °C in 96 mM NaCl, 2 mM KCl, 5 mM HEPES, 1 mM MgCl~2~, 1.8 mM CaCl~2~, and 50 μg/mL gentamycin (pH 7.6) with NaOH\] using two-electrode voltage-clamp recording techniques (OC-725C, Warner Instruments) with a 150 μL recording chamber. Heterologous GABA~A~ receptor and hERG (Kv11.1) manipulations were achieved using previously reported procedures.^[@ref26],[@ref27]^ Nav channel data were filtered at 4 kHz and digitized at 20 kHz using pClamp10 software (Molecular Devices). Microelectrode resistances were 0.5--1 MΩ when the devices were filled with 3 M KCl. The external recording solution contained 100 mM NaCl, 5 mM HEPES, 1 mM MgCl~2~, and 1.8 mM CaCl~2~ (pH 7.6) with NaOH. All experiments were performed at room temperature (RT) (∼22 °C). Leak and background conductances, identified by blocking Na~v~ channels with tetrodotoxin, were subtracted for all of the Na~v~ channel-mediated currents. Chemicals and compounds A--D were obtained from Sigma-Aldrich, Vitasmlabs, and Maybridge (eMolecules).

Analysis of Channel Activity and Drug--Channel Interactions {#sec2.3}
-----------------------------------------------------------

Unless otherwise specified, voltage--activation relationships were obtained by measuring peak currents and calculating conductance (*G*), and a Boltzmann function was fit to the data according to the equation *G*/*G*~max~ = \[1 + e^--*zF*(*V*--*V*~1/2~)/*RT*^\]^−1^, where *G*/*G*~max~ is the normalized conductance, *z* is the equivalent charge, *V*~1/2~ is the half-activation voltage, *F* is Faraday's constant, *R* is the gas constant, and *T* is the temperature in kelvin. Rufinamide and derivatives were dissolved in DMSO (∼5 mg mL^--1^ stock solution) and ad hoc diluted to a working concentration of 100 μM while taking great care not to reach the maximal solubility of the compounds. *Xenopus* oocytes expressing the various Na~v~ channel isoforms were incubated in solutions containing 100 μM drug (final DMSO concentration of ≤1%) for at least 1 h. We did not observe a significant alteration in drug-induced effects on Na~v~ channels between 1 h and overnight incubation. Differences in reported values were only considered significant when *p* \< 0.005 (Student's *t* test). Off-line data analysis and statistical analysis were performed using Clampfit10 (Molecular Devices), Excel (Microsoft Office), and Origin 8 (OriginLab).

Action Potential Threshold Recordings in Hippocampal Neurons {#sec2.4}
------------------------------------------------------------

Hippocampal neurons were dissected from Sprague-Dawley rat embryos on embryonic day 18. Cells were treated with papain (Worthington Biochemical), dissociated with a pipet, and plated over coverslips coated with collagen (Life Technologies) and poly-[d]{.smallcaps}-lysine (Sigma-Aldrich). Astrocyte beds were prepared at a density of 80000 cells/mL and cultured in DMEM (Life Technologies) with 10% fetal bovine serum and 6 mM glutamine for 14 days in 5% CO~2~ at 37 °C. All of the medium was changed every week. Neurons were plated over confluent astrocyte beds at a density of 150000 cells/mL and cultured for 3 weeks in neurobasal medium (Life Technologies) supplemented with B27 and 2 mM glutaMAX. Half of the medium was changed every 3--4 days. Cells were treated for 3 h with compound B in 0.3% DMSO or a control (medium containing 0.3% DMSO) before recording. Coverslips were transferred to a chamber perfused at a rate of 2 mL/min at 32 °C with ACSF containing 140 mM NaCl, 5 mM KCl, 2 mM CaCl~2~, 2 mM MgCl~2~, 10 mM HEPES, and 10 mM glucose (pH 7.3 adjusted with NaOH). An Axopatch 200B instrument equipped with a Digidata 1440 digitizer and pClamp10 software were used. Whole-cell current clamp recordings were performed using borosilicate glass pipettes (4--6 MΩ) filled with a solution containing 135 mM potassium gluconate, 20 mM KCl, 10 mM HEPES, 4 mM Mg-ATP, 0.3 mM Na~2~GTP, and 0.5 mM EGTA. Action potential thresholds were measured by a series of 100 ms, 10 pA depolarizing current injections. At the minimal current injection needed to elicit an action potential, the firing threshold was determined by calculating the potential at which the rate of rise crossed 40 V/s, using AxoGraph X. The input resistance was measured as the slope of the linear range of the current--voltage plot constructed from the steady-state voltage response to depolarizing current injections of 5 pA ranging from −40 to 0 pA with a duration of 500 ms. All cells measured were in the range of 300--500 MΩ, showing no significant difference between treatments (435 ± 38 MΩ for the control and 387 ± 32 MΩ for compound B with *n* = 5 for both sets of experiments). Data are presented as means ± the standard error of the mean. For statistical analysis, a Student's *t* test was performed using GraphPad Prism 6. The Johns Hopkins University Institutional Animal Care and Use Committee approved all experimental protocols involving rats.

Animal Husbandry and Drug Administration {#sec2.5}
----------------------------------------

Male Crl:CF1 mice (10--12 weeks old, Charles River) were housed under a 12 h light--dark cycle with free access to food and water, and all experiments were conducted between 10 a.m. and 4 p.m. 1-(Phenylmethyl)-1*H*-1,2,3-triazole-4-carboxamide-5-methyl (compound B) (Sigma-Aldrich) was suspended in a 40% solution of 2-hydroxypropyl-β-cyclodextrin (Sigma-Aldrich) in sterile saline (0.9%), and 15 min prior to each seizure induction paradigm, compound B (75 mg/kg) was administered via intraperitoneal (ip) injection. Vehicle-treated animals were similarly treated with 40% cyclodextrin and served as the controls for each experiment. The Emory University Institutional Animal Care and Use Committee approved all experimental protocols involving mice.

Seizure Induction Paradigms and Analyses {#sec2.6}
----------------------------------------

### Picrotoxin Seizure Induction {#sec2.6.1}

Fifteen minutes prior to ip injection of picrotoxin (10 mg/kg, Sigma-Aldrich), mice were treated with the vehicle or compound B (*n* = 12 per group). Latencies to the first myoclonic jerk, forelimb clonus, and generalized tonic-clonic seizure were compared between compound B- and vehicle-treated mice. The myoclonic jerk is characterized by a sudden jerk of the upper body, whereas forelimb clonus involves rapid movement of the forelimbs for at least 5 s. Finally, the generalized tonic-clonic seizure involves the loss of postural control with rapid movement of the limbs for at least 5 s.

### Fluorothyl Seizure Induction {#sec2.6.2}

Latencies to fluorothyl-induced seizures were determined as previously described.^[@ref28]^ Briefly, fluorothyl \[2,2,2-trifluoroethyl ether (Sigma-Aldrich)\] was dispensed at a rate of 20 μL/min into a Plexiglas chamber, and latencies to three behavioral phenotypes were compared between vehicle-treated and compound B-treated (75 mg/kg) mice (*n* = 12 per group): (1) the first myoclonic jerk, (2) a generalized tonic-clonic seizure, and (3) a generalized tonic-clonic seizure with tonic extension. Similar to picrotoxin-mediated seizure induction, the myoclonic jerk is the first observable behavioral phenotype followed by the generalized tonic-clonic seizure that is characterized by a loss of postural control with rapid movement of all four limbs for at least 5 s. Lastly, the generalized tonic-clonic seizure with tonic hind limb extension involves the loss of postural control and rapid movement of all four limbs followed by downward extension of the limbs parallel to the body.

### 6 Hz Psychomotor Seizure Induction {#sec2.6.3}

Topical anesthetic (0.5% tetracaine hydrochloride ophthalmic solution) was applied to the cornea 30 min before testing. Fifteen minutes prior to seizure induction, mice were treated with the vehicle or compound B (*n* = 12 per group). Each mouse was manually restrained, and corneal stimulation (0.2 ms pulse, 6 Hz, 3 s) was performed at a current intensity of 17 mA (ECT Unit 57800, Ugo Basile, Comerio, Italy). The mice were observed for behavioral responses immediately following stimulation, and seizures were scored on the basis of a modified Racine scale: 0, no behavior; 1, staring; 2, forelimb clonus; 3, rearing and falling. The mice were randomized into two groups, and in the first trial, one group received the vehicle and the other compound B. The second trial was performed 1 week later, with each group receiving the opposite treatment. The resulting data were combined because no statistically significant differences were observed between the two trials.

### Statistical Analysis {#sec2.6.4}

A Student's *t* test was used to identify statistically significant differences in latencies between vehicle- and compound B-treated groups for each seizure phenotype following administration of fluorothyl and picrotoxin. A Fisher Exact test was applied to determine differences in the percent of vehicle- and compound B-treated mice exhibiting seizures in the 6 Hz seizure induction paradigm, and a Wilcoxon matched-pairs signed rank test determined the differences in seizure severity. All data are presented as means ± the standard error of the mean; *p* values of \<0.05 were considered significant.

Gating characteristics of hNa~v~1.1, hNa~v~1.2, hNa~v~1.3, and hNa~v~1.6 (Figure S1), effect of DMSO on hNa~v~ channel isoforms (Figure S2), effect of rufinamide derivatives on hNa~v~1.1 (Figure S3), evidence of the fact that rufinamide and compound B do not affect hNa~v~1.1 persistent current or activate the α1/β2/γ2 GABAA receptor (Figure S4), evidence that compound B does not influence the tested gating properties of other neuronal Na~v~ channel isoforms (Figure S5), evidence that rufinamide and compound B do not influence hNa~v~1.1 slow inactivation (Figure S6), evidence that rufinamide and compound B do not inhibit hERG channels (Figure S7), lack of an effect of compound B on the tested gating properties of hNa~v~1.2, hNa~v~1.3, and hNa~v~1.6 (Table S1), and evidence that rufinamide and compound B do not influence hNa~v~1.1 slow inactivation (Table S2). This material is available free of charge via the Internet at <http://pubs.acs.org>.
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